TimesSquare Capital Management LLC Has $20.73 Million Stock Holdings in Soleno Therapeutics, Inc. $SLNO

TimesSquare Capital Management LLC boosted its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 19.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 247,369 shares of the company’s stock after buying an additional 40,769 shares during the period. TimesSquare Capital Management LLC owned approximately 0.49% of Soleno Therapeutics worth $20,725,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in SLNO. Adage Capital Partners GP L.L.C. grew its stake in shares of Soleno Therapeutics by 58.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 4,392,696 shares of the company’s stock worth $313,858,000 after purchasing an additional 1,616,720 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Soleno Therapeutics by 47.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,400,418 shares of the company’s stock valued at $171,510,000 after purchasing an additional 769,700 shares in the last quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. bought a new position in shares of Soleno Therapeutics during the 2nd quarter valued at approximately $42,089,000. Invesco Ltd. grew its position in shares of Soleno Therapeutics by 3,789.4% in the first quarter. Invesco Ltd. now owns 467,193 shares of the company’s stock valued at $33,381,000 after purchasing an additional 455,181 shares in the last quarter. Finally, Siren L.L.C. grew its holdings in shares of Soleno Therapeutics by 106.7% during the first quarter. Siren L.L.C. now owns 727,337 shares of the company’s stock worth $51,968,000 after purchasing an additional 375,519 shares in the last quarter. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Soleno Therapeutics Stock Down 2.0%

SLNO stock opened at $47.73 on Thursday. The company has a market cap of $2.56 billion, a P/E ratio of -11.53 and a beta of -2.92. The company has a current ratio of 15.13, a quick ratio of 15.01 and a debt-to-equity ratio of 0.21. Soleno Therapeutics, Inc. has a 52 week low of $41.50 and a 52 week high of $90.32. The company’s 50-day moving average price is $61.12 and its 200 day moving average price is $72.39.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.39. The firm had revenue of $66.02 million for the quarter, compared to analyst estimates of $47.46 million. On average, research analysts expect that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SLNO. The Goldman Sachs Group set a $125.00 price target on Soleno Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Oppenheimer boosted their target price on Soleno Therapeutics from $105.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, August 7th. Wall Street Zen raised Soleno Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Lifesci Capital raised Soleno Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 10th. Finally, Cowen reiterated a “buy” rating on shares of Soleno Therapeutics in a research note on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $114.50.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.